

**What is claimed is:**

1. A method of inhibiting inflammation by administration of a antibodies or antigen-binding fragments which binds at least one mammalian chemokine chosen from CXCL9, CXCL10, CXCL11, CCRL1, CCRL2, CCR5, CCL1, CCL2, CCL3, CCL4, CCL4L1, CCL5, CCL7, CCL8, CCL14-1, CCL14-2, CCL14-3, CCL15-1, CCL15-2, CCL16, CCL19, CCL23-1, CCL23-2, CCL24, CCL26, CCR6, CCL20, CCL25, CCL25-1, CCL25-2, and CCR10 by administration to a mammal in need of anti-inflammatory intervention, of an inflammation-inhibiting effective amount of said antibodies or antigen-binding fragments in a pharmaceutically acceptable carrier.
2. The method of claim 1 wherein the carrier is a liquid.
3. The method of claim 1 wherein said mammal is human.
4. The method of claim 1 wherein the carrier is a solid support.
5. The method of claim 1 wherein said antibodies or antigen-binding fragments are derived from a human, humanized, chimeric antibody.
6. The method of claim 1 wherein said antibodies or antigen binding fragments are administered directly to tissue showing an inflammatory response tissue.
7. A method of treating a mammal with inflammatory disease by the steps of:
  - 1) exposing tissues from said mammal to differing antibodies which bind to specific chemokines,
  - 2) identifying level of expression of each chemokine based on binding of the each of the differing antibodies, and
  - 3) administering to said mammal those specific antibodies which bind to the over-expressed chemokines.
8. The method of claim 7 wherein, in step 3, the antibodies are administered directly to the affected tissue.
9. The method of claim 7 wherein, in step 3, the antibodies are administered parenterally.
10. The method of claim 7 wherein the antibodies are admin-

istered in a liquid carrier.

11. The method of claim 7 wherein the antibodies are administered on a solid support.

12. A method of treating a mammal with inflammatory disease by the steps of:

1) identifying the level of particular chemokines using PCR,

2) administering to said mammal those specific antibodies which bind to the over-expressed chemokines in a pharmaceutically acceptable carrier.

13. The method of claim 12 wherein the antibodies are administered directly to the affected tissue.

14. The method of claim 12 wherein the antibodies are administered systemically.

15. The method of the invention wherein the antibodies are administered on a solid support.

15. The method of claim 12 wherein the